UnitedHealth Group

UnitedHealth’s leadership is experienced and aligned with shareholders. CEO Andrew Witty (ex-Glaxo) grew the business since 2021 (revenue up to $400B), though he stepped down in 2025 amid margin surprises. Now Stephen Hemsley (former CEO/chairman, long tenure since 2006) has resumed leadership to steady operations.

Both have deep appreciation for the industry. The management team generally communicates clearly: for example, UNH revised guidance promptly when facing cost pressures, showing disciplined oversight. Board governance is strong. The CEO and longtime executives hold significant stock, aligning interests.

One negative: UNH has faced unusual crises (a cyberattack, the tragic death of an executive, and a DOJ investigation) – not due to mismanagement per se but requiring leadership skill. Overall we view management as capable: they made bold moves (growing Optum, acquisitions, pricing strategies) and are now correcting course where needed.

The lack of a founder-CEO slightly lowers alignment, but Hemsley’s stock ownership and tenure mimic founder characteristics. We score management as strong.